.jetcityimage/iStock Content using Getty Images Morgan Stanley has actually opted for Eli Lilly (NYSE: LLY) as its best biopharma selection for 2025 as well as ranked one more nine labels in the room as overweight. The expenditure bank claimed in a details that it continues to believe “diabesity is actually set to come to be.